Medtronic has announced that its MiniMed 360G system with SmartGuard technology has been launched in the United States.
“This latest innovation demonstrates Medtronic’s vision to transform diabetes care to enable greater freedom and better health through a commitment to continually improving both outcomes and user experience,” Alejandro Galindo, president of the intensive insulin management business at Medtronic, said in a press release.
The FDA approved the system for the treatment of patients aged at least 16 years with diabetes. The new system features an insulin pump hardware platform and user-friendly design that will combine personalized diabetes management with industry-leading clinical performance, according to the release.
The system uses the Contour Next Link 2.4 blood glucose meter from Ascensia Diabetes Care to provide highly accurate blood glucose test results. Results are transmitted to calculate boluses using the Bolus Wizard calculator to calibrate the continuous glucose monitor sensor to help prevent manual entry errors, according to the release.
The SmartGuard technology is designed to trigger an alarm when continuous glucose monitoring levels reach a low threshold and releases insulin if the patient is unaware of the alarm.
“Low blood sugar at night is of particular concern, when up to 75% of severe hypoglycemia occurs and patients are unlikely to be aware of symptoms while they are asleep,” Satish Garg, MD, editor-in-chief of Diabetes Technology & Therapeutics and professor of pediatrics and medicine and director of the adult diabetes program at the University of Colorado Denver, Barbara Davis Center for Childhood Diabetes, said in the release. “The ability to automate the suspension of insulin at night is an important feature, as prolonged hypoglycemia could be life-threatening.”